CoreCap Advisors’s Avalo Therapeutics AVTX Stock Holding History

CoreCap Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$199	Buy	+13	New	+$239	﹤0.01%	2956

Other funds holding AVTX

PFS Partners Mine Hill, New Jersey $246M AUM 22.61% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

CoreCap Advisors's AVTX Position: Q3 2026 in Review

CoreCap Advisors opened a new position in Avalo Therapeutics (AVTX) in Q3 2026: 13 shares worth $199. The stake represents ﹤0.01% of the portfolio and ranks #2956 among its holdings.

10 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

CoreCap Advisors held 13 shares of Avalo Therapeutics worth $199 as of Q3 2026.
Avalo Therapeutics was a new CoreCap Advisors position in Q3 2026.
Avalo Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2956 holding.
10 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.